Furthermore, our observation of the lack of PAR-mediated cell death in breast cancer cells after TRPM2 inhibition, along with the observation by Zeng et al of the failure of PAR to mediate TRPM2 function in prostate cancer cells, appears to corroborate this novel role in both breast and prostate cancer cells. This evidence concerns the gene TRPM2 and prostate carcinoma.